why choose us

First received: January 18, 2023

Clinical Trial: SIRT With Tremelimumab and Durvalumab for Resectable HCC

Study Status: Completed

Recruit Status: RECRUITING

Condition: Resectable Hepatocellular Carcinoma

Study Type: INTERVENTIONAL


Official Title: A Phase 1 Neoadjuvant Trial of Selective Internal Yttrium-90 Radioembolization (SIRT) With Tremelimumab and Durvalumab (MEDI4736) for Resectable Hepatocellular Carcinoma

Brief Summary: The goal of this research study is to evaluate the safety and tolerability of tremelimumab and durvalumab with or without Selective Internal Yttrium-90 Radioembolization (SIRT) in participants with resectable hepatocellular carcinoma (HCC) who will undergo liver surgery.The names of the interventions involved in this study are:Durvalumab (a type of immunotherapy)Tremelimumab (a type of immunotherapy)Selective Internal Yttrium-90 Radioembolization (SIRT) (a type of radiation microsphere bead)

Read more